earnings
confidence high
sentiment positive
materiality 0.75
NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%
NEUROONE MEDICAL TECHNOLOGIES Corp
2025-Q2 EPS
reported -$0.02
vs consensus -$0.31
▲ beat
(+93.5%)
- Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.
- Q2 product gross margin 55.6% vs 28.3% YoY; FY25 guidance reaffirmed ($8-10M revenue).
- Filed 510(k) for OneRF Trigeminal Nerve Ablation System for facial pain ahead of schedule; potential revenue in late CY2025.
- Raised $8.2M net in oversubscribed institutional offering in April; cash $9.4M post-raise; debt-free.
- Hired Dr. Parag Patil as Chief Medical Advisor and Emily Johns as General Counsel.